Compare

Peptide Comparisons

Neutral, side-by-side comparisons of peptide compounds by drug class, regulatory status, evidence grade, and tracked clinical trials. No efficacy claims or recommendations.

A comparison sets two peptides side by side by drug class, regulatory status by region, evidence grade, and the volume of tracked clinical trials. These pages report classification and status only, not efficacy or recommendations.

  1. BPC-157 vs TB-500Synthetic stable gastric pentadecapeptide (15-amino-acid partial sequence derived from a protein in human gastric juice) · Synthetic peptide fragment (Ac-LKKTETQ) corresponding to the actin-binding region of thymosin beta-4; note it is NOT the same molecule as full-length recombinant thymosin beta-4
  2. Cagrilintide vs RetatrutideLong-acting amylin (and calcitonin) receptor agonist / amylin analogue · Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)
  3. Cagrilintide vs SemaglutideLong-acting amylin (and calcitonin) receptor agonist / amylin analogue · Glucagon-like peptide-1 (GLP-1) receptor agonist
  4. CJC-1295 vs IpamorelinGrowth hormone-releasing hormone (GHRH) analog · Growth hormone secretagogue; ghrelin (GHS-R1a) receptor agonist (pentapeptide)
  5. Dulaglutide vs SemaglutideLong-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment) · Glucagon-like peptide-1 (GLP-1) receptor agonist
  6. GHRP-2 vs GHRP-6Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP) · Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys)
  7. GHRP-6 vs HexarelinSynthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys) · Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP) hexapeptide
  8. Ipamorelin vs SermorelinGrowth hormone secretagogue; ghrelin (GHS-R1a) receptor agonist (pentapeptide) · Synthetic analogue of growth hormone-releasing hormone comprising its first 29 amino acids (GHRH 1-29); formerly FDA-approved (Geref), later withdrawn from the US market
  9. Liraglutide vs SemaglutideGlucagon-like peptide-1 (GLP-1) receptor agonist (acylated GLP-1 analogue) · Glucagon-like peptide-1 (GLP-1) receptor agonist
  10. Liraglutide vs TirzepatideGlucagon-like peptide-1 (GLP-1) receptor agonist (acylated GLP-1 analogue) · Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide)
  11. Melanotan II vs PT-141 (Bremelanotide)Synthetic cyclic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH); non-selective melanocortin receptor agonist · Melanocortin receptor agonist; synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH)
  12. Orforglipron vs SemaglutideOral small-molecule (non-peptide) agonist of the glucagon-like peptide-1 (GLP-1) receptor · Glucagon-like peptide-1 (GLP-1) receptor agonist
  13. Retatrutide vs SemaglutideTriple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide) · Glucagon-like peptide-1 (GLP-1) receptor agonist
  14. Retatrutide vs SurvodutideTriple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide) · Dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors (investigational metabolic peptide)
  15. Retatrutide vs TirzepatideTriple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide) · Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide)
  16. Selank vs SemaxSynthetic tuftsin analog (heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro); anxiolytic/nootropic neuropeptide · Synthetic ACTH(4-10) analog (heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro); nootropic/neuroprotective neuropeptide
  17. Semaglutide vs TirzepatideGlucagon-like peptide-1 (GLP-1) receptor agonist · Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide)
  18. Amycretin vs CagrilintideUnimolecular GLP-1 and amylin receptor co-agonist · Long-acting amylin (and calcitonin) receptor agonist / amylin analogue
  19. Amycretin vs RetatrutideUnimolecular GLP-1 and amylin receptor co-agonist · Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)
  20. Amycretin vs SemaglutideUnimolecular GLP-1 and amylin receptor co-agonist · Glucagon-like peptide-1 (GLP-1) receptor agonist
  21. Cagrilintide vs PramlintideLong-acting amylin (and calcitonin) receptor agonist / amylin analogue · Synthetic amylin analog (amylinomimetic)
  22. Cagrilintide vs PetrelintideLong-acting amylin (and calcitonin) receptor agonist / amylin analogue · Long-acting amylin (islet amyloid polypeptide) receptor agonist for weight management
  23. Dulaglutide vs EfpeglenatideLong-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment) · Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly)
  24. Efpeglenatide vs SemaglutideLong-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly) · Glucagon-like peptide-1 (GLP-1) receptor agonist
  25. Exenatide vs LixisenatideGlucagon-like peptide-1 (GLP-1) receptor agonist; synthetic exendin-4 · Short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-4 based incretin mimetic)
  26. Lixisenatide vs SemaglutideShort-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-4 based incretin mimetic) · Glucagon-like peptide-1 (GLP-1) receptor agonist
  27. Maridebart cafraglutide vs RetatrutidePeptide-antibody conjugate with GLP-1 receptor agonist and GIP receptor antagonist activity · Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)
  28. Maridebart cafraglutide vs TirzepatidePeptide-antibody conjugate with GLP-1 receptor agonist and GIP receptor antagonist activity · Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide)
  29. Abaloparatide vs TeriparatideSynthetic parathyroid hormone-related protein (PTHrP 1-34) analog; osteoanabolic agent · Recombinant human parathyroid hormone fragment PTH(1-34); bone-forming (anabolic) osteoporosis agent
  30. Lanreotide vs OctreotideLong-acting synthetic somatostatin analog (cyclic octapeptide) · Synthetic somatostatin analog (octapeptide); inhibitor of growth hormone and gastroenteropancreatic hormone secretion